Biotech Showcase™ 2016: Grünenthal reveals plans to maintain robust growth following strong 2015

February 2, 2016
While other pharma majors have struggled against a number of headwinds, Grünenthal GmbH saw a solid year of growth in 2015 with anticipated revenues of some EUR 1.2 billion. Speaking to Informa Pharma Insight’s global director of content Mike Ward at the recent Biotech Showcase, Grünenthal’s CSO, Dr. Klaus Langner, explains what underpinned this performance as well as discussing the company’s plans to expand beyond its core strength in pain management to niche therapeutic fields. Plans include increasing investment in R&D, establishing new partnerships and licensing agreements to bolster the pipeline and existing product portfolios to access assets identified by a four-person innovative medicines unit. Dr. Langner also explains how Grünenthal is on the brink of entering the European hospital market, having received EU marketing authorization for Zalviso, a pre-programmed, non-invasive device the company in-licensed from AcelRx for the management of acute moderate to severe post-operative pain in adult patients. Zalviso is poised for launch in the first half of 2016. Dr. Langner also details the ambitious growth goals the company has for the US hospital market, through strategic partnerships, as well as increasing its footprint in Latin America. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Corbus sees 2016 as pivotal year
Biotech Showcase™ 2016: Corbus sees 2016 as pivotal year

With key clinical data readouts expected at the end of 2016 and the start of 2017, Corbus Pharmaceuticals H...

Next Video
Biotech Showcase™ 2016: Faron Pharmaceuticals crosses Finnish line to increase global footprint
Biotech Showcase™ 2016: Faron Pharmaceuticals crosses Finnish line to increase global footprint

Having raised GBP 10 million floating on London’s AIM in November 2015, Finland’s Faron Pharmaceuticals is ...